A Multicenter, Randomized, Double-Blind, Secukinumab-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis
Status: Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 05 Dec 2019
Price : $35 *
At a glance
- Drugs Bimekizumab (Primary) ; Secukinumab
- Indications Plaque psoriasis
- Focus Registrational; Therapeutic Use
- Acronyms BE RADIANT
- Sponsors UCB Biopharma
- 11 Oct 2019 Planned End Date changed from 1 Aug 2020 to 1 May 2022.
- 10 May 2019 Status changed from recruiting to active, no longer recruiting.
- 14 Jun 2018 Status changed from not yet recruiting to recruiting.